Guggenheim Maintains Buy on Sagimet Biosciences, Raises Price Target to $26
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Guggenheim analyst Seamus Fernandez maintains Sagimet Biosciences (NASDAQ:SGMT) with a Buy and raises the price target from $25 to $26.
Guggenheim analyst Seamus Fernandez maintains Sagimet Biosciences (NASDAQ:SGMT) with a Buy and raises the price target from $25 to $26.